[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhejiang Wenda Pharma Technology LTD.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,64,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644685","phase-3-a-multicenter-randomized-double-blind-placebo-controlled-phase--study-to-evaluate-the-efficacy-and-safety-of-wd-890-tablets-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-100644685",false,"NCT07672561","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male or female participant aged 18 to 75 years(inclusive)at the time of informed consent.\n* Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.\n* Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization\n\nExclusion Criteria:\n\n* Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)\n* Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted\n* Class III or IV congestive heart failure by New York Heart Association Criteria",true,"ALL","18 Years","75 Years",{"count":20,"type":21},375,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.",[27],"Moderate to Severe Plaque Psoriasis","RECRUITING","2026-06-26",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2026-03-18",{"date":36,"type":21},"2027-07-30",{"name":38,"class":39},"Zhejiang Wenda Pharma Technology LTD.","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100586191","phase-2-a-study-of-wd-890-in-participants-with-moderate-to-severe-plaque-psoriasis-100586191","NCT06912165","A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male or female participant aged 18 to 70 years(inclusive)at the time of informed consent.\n* Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.\n\n  ≥10% of BSA involvement at screening visit and randomization;\n* Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization\n\nExclusion Criteria:\n\n* Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)\n* Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted\n* Class III or IV congestive heart failure by New York Heart Association Criteria\n* Participant with a history of chronic bacterial infections (e.g., chronic pyelonephritis, chronic bronchiectasis, or chronic osteomyelitis).","70 Years",{"count":50,"type":21},140,[52],"PHASE2","Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.",[55],"Brief Description of Focus of Study","2025-04-08",{"date":58,"type":32},"2025-04-11",{"date":60,"type":32},"2024-12-31",{"date":62,"type":21},"2025-11-30",{"name":38,"class":39},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":40},"100585088","phase-1-a-phase-i-randomised-double-blind-placebo-controlled-single-and-multiple-ascending-dose-study-to-evaluate-the-safety-tolerability-pharmacokinetics-pharmacodynamics-and-food-effect-of-wd-910-in-healthy-participants-100585088","NCT06897813","A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants","Inclusion Criteria:\n\n* Aged 18 to 55 years (inclusive) at the time of informed consent.\n* Body mass index (BMI) between 18 to 32 kg\u002Fm2 and male participant with body weight of ≥ 50.0 kg, female participant with body weight ≥ 45.0 kg\n\nExclusion Criteria:\n\n* Any major surgery within 12 weeks prior to Day 1, or any planned surgery during the study.\n* Poor pill swallowing ability","55 Years",{"count":72,"type":21},68,[74],"PHASE1","This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed",[77],"Healthy Participants","NOT_YET_RECRUITING","2025-03-26",{"date":81,"type":32},"2025-04-02",{"date":83,"type":21},"2025-06-30",{"date":85,"type":21},"2025-12-31",{"name":38,"class":39},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":93,"maxAge":18,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":40},"100556607","phase-2-a-multicenter-open-label-single-arm-phase-ii-study-of-nhwd-870-hcl-in-adults-and-adolescents-with-advanced-nut-cancer-100556607","NCT06527300","A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer","Inclusion Criteria:\n\n* A written informed consent signed;\n* Subjects must sign and date IEC-approved written informed consent in accordance with the guidelines of the competent authorities and research institutions. Informed consent had to be obtained before any protocol-related procedure that was not part of a participant's routine care was performed.\n* Participants must be willing and able to comply with the scheduled visits, treatment protocols, laboratory tests, and other requirements of the study;\n* If the subjects were under 18, the participants and their legal guardian authorization signed agreement;\n* Both sexes, the first part (adult group) was ≥18 years old and ≤75 years old, the second part (adolescent group) was ≥12 years old and \\\u003C18 years old;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;\n* The expected survival period for 3 months or more;\n* The histopathological (histopathological diagnosis was the first time according to the tumor tissue pathologic specimens before three years, if more than 3 years should be confirmed in the center of the study to do a biopsy. If, in the investigator's judgment, a biopsy might increase a subject's risk, archival tumor tissue samples up to 3 years old could be collected after discussion with the sponsor) were diagnosed as midline (NUT) cancer by, but not limited to:\n* Determination of ectopic NUT protein expression by IHC;\n* Detection of NUT gene translocations by fluorescence in situ hybridization (FISH);\n* Detection of NUT gene translocations (e.g. BRD3\u002F4 mutation or ≥ 2-fold amplification) by DNA\u002FRNA sequencing.\n\nExclusion Criteria:\n\n* Prior treatment with a BET inhibitor;\n* 3 years before into the group suffering from other malignant tumors, with the exception of removal of cure of basal cell carcinoma, orthotopic bladder cancer or cervical carcinoma in situ;\n* The researchers believe the subjects is the need for systemic anti-infection treatment of active infection;\n* Patients with clinically significant bleeding symptoms or clear bleeding tendency within 3 months before enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, etc.\n* Imaging shows that the tumor has invaded important blood vessels or the investigators judge that the tumor is likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study.","12 Years",{"count":95,"type":21},48,[52],"This is a multicenter, open-label, single-arm, phase II study to evaluate the efficacy, safety, and pharmacokinetics of NHWD-870 HCl in adults and adolescents with advanced NUT cancer.",[99],"Advanced Solid Tumor (Phase 1)",[101],"NHWD-870","2025-01-21",{"date":104,"type":32},"2025-01-24",{"date":106,"type":32},"2024-04-25",{"date":108,"type":21},"2025-12-30",{"name":38,"class":39},""]